K
Klaus Zöphel
Researcher at Dresden University of Technology
Publications - 111
Citations - 2852
Klaus Zöphel is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Standardized uptake value & Prostate cancer. The author has an hindex of 26, co-authored 107 publications receiving 2461 citations. Previous affiliations of Klaus Zöphel include German Cancer Research Center & Helmholtz-Zentrum Dresden-Rossendorf.
Papers
More filters
Journal ArticleDOI
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer
Daniel Zips,Klaus Zöphel,Nasreddin Abolmaali,Rosalind Perrin,Andrij Abramyuk,Robert Haase,Steffen Appold,Jörg Steinbach,Jörg Kotzerke,Michael Baumann +9 more
TL;DR: It is demonstrated that FMISO-PET/CT imaging during the initial phase of treatment carries strong prognostic value and could be promising way to select patients that would benefit from hypoxia modification or dose-escalated treatment.
Journal ArticleDOI
A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling.
Stefan Leger,Stefan Leger,Alex Zwanenburg,K. Pilz,Fabian Lohaus,Annett Linge,Klaus Zöphel,Klaus Zöphel,Jörg Kotzerke,Jörg Kotzerke,Andreas Schreiber,Inge Tinhofer,Inge Tinhofer,Volker Budach,Volker Budach,Ali Sak,Ali Sak,Martin Stuschke,Martin Stuschke,Panagiotis Balermpas,Panagiotis Balermpas,Claus Rödel,Claus Rödel,Ute Ganswindt,Ute Ganswindt,Claus Belka,Steffi Pigorsch,Steffi Pigorsch,Stephanie E. Combs,Stephanie E. Combs,David Mönnich,David Mönnich,Daniel Zips,Daniel Zips,Mechthild Krause,Michael Baumann,Esther G.C. Troost,Steffen Löck,Steffen Löck,Steffen Löck,Christian Richter +40 more
TL;DR: A subset of algorithms are identified which should be considered in future radiomics studies to develop stable and clinically relevant predictive models for time-to-event endpoints.
Journal ArticleDOI
18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
TL;DR: An overview of the performance of choline and acetate PET for staging the primary and recurrent disease and lymph nodes in PCA, based on the literature of the last 10 years is provided.
Journal ArticleDOI
Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?
TL;DR: The therapeutic effect of isotretinoin in thyroid cancer is certainly less than previously reported and an indiscriminate use in all patients with otherwise untreatable thyroid cancer cannot be recommended.
Journal ArticleDOI
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.
Maria Hentschel,Steffen Appold,Andreas Schreiber,Nasreddin Abolmaali,Andrij Abramyuk,Wolfgang Dörr,Joerg Kotzerke,Michael Baumann,Klaus Zöphel +8 more
TL;DR: The decrease of SUVmax from before (0 Gy) to week 1 or 2 (10 or 20 Gy) of CRT is a potential prognostic marker for patients with HNSCC and is suggested for the use of GTV PET, especially ΔSUVmax10/20, for an early estimation of therapy outcome.